Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Laboratorium Ofichem B.V","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Acquires DMT Clinical Study from Entheon Biomedical","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Entheon Biomedical

    Menu

    Entheon Biomedical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Entheon Biomedical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

              Details:

              This DMT study, which is the largest to date, is expected to accelerate the clinical development path of CYB004, Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, by approximately nine months.

              Lead Product(s): Deuterated Dimethyltryptamine

              Therapeutic Area: Psychiatry/Psychology Product Name: CYB004

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cybin

              Deal Size: $1.1 million Upfront Cash: Undisclosed

              Deal Type: Acquisition July 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Entheon Biomedical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cybin Acquires DMT Clinical Study from Entheon Biomedical

              Details:

              Pending the close of the Acquisition, the CYB004-E study is expected to yield essential safety and dosing optimization data and will replace Cybin’s planned pilot study for CYB004 that was expected to commence in the third quarter of 2022.

              Lead Product(s): Deuterated Dimethyltryptamine

              Therapeutic Area: Psychiatry/Psychology Product Name: CYB004

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cybin

              Deal Size: $1.2 million Upfront Cash: Undisclosed

              Deal Type: Acquisition June 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Entheon Biomedical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

              Details:

              Formulation and stability testing of DMT drug product by CHDR's partner pharmacy has commenced in accordance with projected start date of EBRX-101(N, N-dimethyltryptamine), a study that will evaluate controlled intravenous infusion of population of healthy smokers.

              Lead Product(s): Dimethyltryptamine

              Therapeutic Area: Psychiatry/Psychology Product Name: EBRX-101

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Laboratorium Ofichem B.V

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY